Avicanna is focused on the medical and wellness cannabis markets.
Avicanna was the first company focused on medical cannabis that was invited to Johnson & Johnson’s JLabs where the company has their R&D HQ.
FACILITIES:
360,000 sq ft of cultivation in Colombia which is GACP-certified.
OWNERSHIP:
Santa Marta Golden Hemp JV – 60% ownership of with El Grupo Daabon for the cultivation and processing of cannabis with 300,000 square feet of cultivation. Santa Marta Colombia is USDA National Organic Program certified as well as GACP certified.
Aureus Santa Marta is Avicanna’s in-house, low cost brand which cultivates and extracts its supply of cannabinoids for its finished products from its 180,000 sq ft of cultivation. They provide pharmaceutical partners with API’s and have exported into 16 international markets.
NEWS & PARTNERSHIPS:
2018
The company acquired a 60% stake in Santa Marta Golden Hemp.
2019
The company entered into a 61%-owned by Avicanna, JV with Sigma Analytical for the establishment of the first GMP/GLP level cannabis quality assurance laboratory in South America which will test for pesticides, heavy metals, residual solvents, aflatoxins, microbial, genotyping as well as cannabinoid and terpene profiling.
The company entered into an importation and distribution agreement with LYPHE Group for the UK market. The companies will collaborate on medical education programs with a focus on safety, dose guidance and efficacy.
Pura Earth derma-cosmetics became available in approximately 60 retail locations throughout Colombia, including Blind prestige beauty shops and Cromantic professional beauty markets.
The company signed a 3-year exclusive license with Kings Garden Inc to use the RHO Phyto trademark and to manufacture, market, distribute and sell the RHO Phyto advanced formulation products in the State of California. Under the agreement, Avicanna is to receive 40% of the net profits from the sale of the products.
2020
The company entered into a 3-year multi-faceted strategic manufacturing agreement with MediPharm Labs involving production for domestic and international distribution of Pura Earth and RHO Phyto products as well as intellectual property licensing of the company’s formulations allowing MediPharm to develop additional products and white labelling for the domestic and international market.
The company launched a medical cannabis program with its RHO Phyto formulary nationwide in Colombia available through physician prescription under the Magisterial model.
RHO Phyto started selling at Medical Cannabis by Shoppers Drug Mart.
The company exported 7 million CBG dominant seeds to the US from Colombia.
The company entered into an importation and distribution agreement with Cannvalate for the exclusive supply of RHO Phyto medical cannabis products into the Australian market. Avicanna also agreed to supply Cannvalate with a line of advanced cannabinoid phyto-therapeutic products under white labelling.
The company entered into an exclusive 5-year partnership with Red, White and Bloom for the distribution and commercialization of Pura H&W CBD-based topical products in the US.
The company expanded their distribution network in Ecuador through an exclusive partnership with Alliancepharma Technologies S.A.
The company signed a distribution agreement with Spanta S.A. in Ecuador for the distribution of its derma-cosmetic products under the Pura Earth brand in pharmacies, beauty retailers and e-commerce platforms.
The company signed a distribution agreement with Spenta S.A. for the distribution of Pura Earth.
The company announced an importation and distribution agreement with Alliancepharma Technologies S.A. for the distribution of Avicanna’s medical and pharmaceutical formulations in Ecuador.
The company entered an agreement with a US distributor for sublingual and sustained released tablets intended for the sleep market which the US distributor will use the developmental IP to manufacture, distribute and market the products and will pay Avicanna a royalty payment based on the gross revenue of the products. Avicanna will have the opportunity to supply the needed cannabinoids for the manufacture of the products.
The company announced an agreement with Medical Cannabis by Shoppers for the exclusive distribution of Avicanna’s RHO Phyto and Pura Earth products for the Canadian market while at the same time collaborating on providing the Canadian medical community and patients with education, training and on-going support.
2021
Aureus has exported probably the first commercial export of cannabis extracts with THC from Colombia to Peru.
Viola Brands launched nationwide in Canada through a partnership with the company on the Medical Cannabis by Shoppers online platform.
The company exported CBD and CBG products into Paraguay.
THC extracts under the Aureus brand was exported to Austria.
The company started a master service agreement within a pharmaceutical epilepsy program collaboration at The University Health Network with the Krembil Research Institute and Dr. Peter Carlen which is supported by a Mitacs Accelerate program grant and involves the analysis of RHO Phyto cannabinoid-based products for the efficacy on comorbidities and seizure control in addition to identifying optimized cannabinoid and non-cannabinoid ratios for future drug development.
The company launched Pura H&W in the US through an exclusive partnership with Red White and Bloom.
The company announced a 3-year supply agreement covering industrial volumes with a Brazilian pharmaceutical company with THC and CBD cannabis extracts
The company entered into a 3-year exclusive licensing and royalty agreement with Heritage Cannabis Holdings to commercialize the company’s topical products through Heritage’s medical cannabis channels. The company’s evidence-based CBD topical products, including its deep tissue and skin care formulations will be used by Heritage to sell under non-compete medical channels in Canada under the Opticann brand. Heritage will pay a fee for each product produced and a royalty for each product sold.
The company signed a distribution partnership with Bryden Stokes Limited for RHO Phyto products starting wtih Barbados with plans to expand into other Caribbean nations.
The company made an agreement with Sunnybrook Hospitals Odette Cancer Centre pharmacy to supply major Canadian hospitals with RHO Phyto medical cannabis products supported by education, training, and patient support programs. The collaborative program will establish a complete cannabis consultation and dosing regimen provided through the expertise of Avicanna’s medical team and the Sunnybrook Hospital pharmacy team.
The company entered into a licensing and distribution agreement for its intellectual property and supply of its active pharmaceutical ingredients with an established pharmaceutical company in Argentina for the commercialization of Trunerox in Argentina. The partner will exclusively source its pharmaceutical-grade CBD from Avicanna.
The company exported feminized cannabis seeds from Colombia to Peru and Argentina.
The company announced the launch of the brand re+PLAY, the brand was founded by Al Harrington and offers CBD-topical products such as a muscle rub, total body cream and a foot & ankle cream in Canada.
The company executed on 3-year supply agreement with THC and CBD cannabis extracts for a Brazilian pharmaceutical company.
2022
The company exported feminized cannabis seeds to Lesotho.
The company entered into an exclusive license and supply agreement with an established South American pharmaceutical company for the commercialization of up to 4 of of Avicanna’s proprietary cannabinoid-based pharmaceutical preparations.
Pura H&W advanced its research partnership with Bio-Gate AG and expanded into the EU with them through a 5-year exclusive distribution agreement for Pura H&W branded CBD derma-cosmetics.
The company announced a royalty agreement for the Psilly brand with Ei. Ventures for the development and commercialization of fungi-based products, with an initial focus on functional, apoptogenic, fungi-based formulations in the form of consumer friendly and single dosed products.
The company started a research collaboration with the University of Toronto on cannabinoids and their anti-seizure properties in the field of epilepsy.
The company introduced Avicenna Academy, its no-cost medical cannabis education online portal for health care professionals.
The company exported feminized CBD, CBG and THC cannabis seeds to Lesotho.
The company entered into a master supply agreement with Pioneer Knop Laboratorios S.A. for the supply of a range of cannabinoid-based active pharmaceutical ingredients.
The company developed a THC beverage infuser under the Viola brand from patent-pending, water-soluble technology called Influid, now available in the Canadian market.
2023
The company launched the MyMedi.ca platform with 35 brands and over 200 SKU’s.
The company acquired Medical Cannabis by Shopper’s business unit from major Canadian pharmacy chain Shoppers Drug Mart and transitioned it into MyMedi.ca.
The company entered into a sponsorship agreement with the Canadian Consortium for the Investigation of Cannabinoids involving the sponsoring of a medical cannabis education and training campaign in Canada for the Canadian Cannabis Syllabus to made available to the Canadian medical community.
The company executed a master service agreement with Northern Green Canada for the operationalization of MyMedi.ca’s logistics and fulfilment infrastructure in Canada.
The company shipped its first commercial export of feminized cannabis seeds to Spain.
The company announced a cannabinoid-based translational research collaboration and NSERC grant with Langara College which will focus on Avicanna’s proprietary formulations and pharmaceutical pipeline. The collaboration was awarded a peer-reviewed grant from the Natural Sciences and Engineering Research Council of Canada Applied Research and Development Grant for a period of two years starting Q2 2023.
The company expanded its partnership with Viola Brands to exclusively commercialize its Viola-branded products in the UK where they have entered into a sub-licensing agreement with IPS Pharma for the manufacturing and distribution of the products.
The company exported products from its Aureus brand containing CBD And CBG to Paraguay.
The company expanded the strategic manufacturing agreement with Medipharm Labs for the commercialization of Avicanna’s proprietary SEDDS technology capsules under GMP-standards to sell under the RHO Phyto brand, in Canada through medical channels including Avicanna’s online cannabis care platform, MyMedi.ca and MediPharm’s Canna Farms platform. Medipharm in turn, intends to commercialize the capsules across adult use wellness channels under its MediPharm Labs brand. Products will be produced by MediPharm Labs under GMP standards and each company can offer their own products internationally.
2024
Trunerox got the first indication-specific drug registration by INVIMA, Colombia’s health authority.
The company announced an exclusive supply agreement for its Ultra-CBD cream and CBG Transdermal Gel under the RHO Phyto with a multinational pharmaceutical company for sales in 6 European countries with expectations of further expansion.
The company entered into a research collaboration with a multi-national European-based pharmaceutical company. The collaboration will initially assess the Company’s proprietary SEDDS technology in combination with the collaborator’s various drug delivery and pharmaceutical formats to gain a better understanding of proprietary dosage forms with precisely standardized delivery and enhanced bioavailability of cannabinoids. Avicanna will provide services for assessing a range of other formulations that may be included in the collaborator’s portfolio.
The company exported Aureus-branded CBG products into Singapore.
The company received US patent No. 20230025693A1 which is part of the company’s RHO Phyto commercial portfolio. The patented technology enhances the transdermal diffusion of cannabinoids through the epidermis and into sub-epidermal layers. This is accomplished by encapsulating cannabinoids within a nano- and micro-metric emulsion system with penetration enhancers, which are then stabilized in a gel matrix. The water-based gel leverages Avicanna’s proprietary deep tissue technology, combining cannabinoids with synergistic terpenes and natural excipients to maximize therapeutic outcomes.
2025
The company announced a strategic scientific and medical affairs collaboration agreement with Vectura Fertin Pharma, a subsidiary of Phillip Morris which is aimed at improving the understanding of medical cannabis access and applications in Canada through prioritiizing engagement with the Canadian medical community, including patients and insurers to gain insights into the challenges associated with accessing medical cannabis and Mymedi.ca will play a key role in improving access and patient support. This is made possible through the establishment of a joint scientific and medical affairs committee which will facilitate research studies through which evidence-based educational resources will be produced.
2026
Santa Marta Golden Hemp exported its first non-psychoactive CBD dominant cannabis flower in the form of 3 proprietary varieties to Switzerland.
BRANDS:
Pura Earth is Avicanna’s novel skincare line utilizing a combination of CBD and hemp oil as well as other key ingredients designed to provide natural regulatory effect, nourishment and rejuvenation to the skin. The brand offers a beauty line as well as a moisture & protection line.
Aureus offers a range of CBD, THC and CBG extracts as well as feminized seeds.
RHO-Phyto is a medical and wellness cannabis brand with advanced drug delivery platforms, evidence-based with pre-clinical data with accurate dosing & easy to use with long-term stability and consistency commercially available across 3 national medical channels and retail channels across 5 provinces in Canada. Products offered are water-soluble infusers, oil drops, transdermal gels, capsules, tablets, sublingual sprays and local creams. The biggest medical channel is through a strategic partnership with Medical Cannabis by Shoppers which is Canada’s leading pharmacy retailer with over 30,000 registered cannabis patients.